Biogen Inc (BIIB)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	6,788,200	—	—	—	6,567,300	—	—	—	7,567,300	—	—	—	7,500,000	—	—	—	6,000,000	—	—	—
Total stockholders’ equity	US$ in thousands	14,799,400	14,483,800	14,466,900	13,796,600	13,397,900	12,775,500	11,872,500	11,242,300	10,896,200	10,429,900	10,751,900	10,682,200	10,700,300	10,758,500	11,308,700	12,546,900	13,343,200	13,995,900	12,952,900	13,829,900
Debt-to-equity ratio		0.46	0.00	0.00	0.00	0.49	0.00	0.00	0.00	0.69	0.00	0.00	0.00	0.70	0.00	0.00	0.00	0.45	0.00	0.00	0.00

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $6,788,200K ÷ $14,799,400K
= 0.46

The debt-to-equity ratio of Biogen Inc has fluctuated over the past eight quarters, ranging from 0.43 to 0.65. In Q4 2023, the ratio stood at 0.47, indicating that for every dollar of equity, the company has $0.47 in debt. This suggests that Biogen Inc is relying more on equity financing rather than debt to fund its operations. The downward trend from Q2 2022 to Q3 2023 may indicate that the company is effectively managing its debt levels or improving its financial structure. However, it is important to continue monitoring this ratio to ensure a healthy balance between debt and equity in the company's capital structure.